DAVID HOLLOWAY: Open Payments
NPI 1821195777 · WAUKESHA, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,091 in 181 payments from 17 companies in 2025. Trend: 2023 $2,192 · 2024 $2,201 · 2025 $3,091
Food & beverage: $3,085Education: $7
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 22 | $393 |
| ABBVIE INC. | 19 | $350 |
| Teva Pharmaceuticals USA, Inc. | 13 | $307 |
| Vanda Pharmaceuticals Inc. | 26 | $300 |
| Otsuka America Pharmaceutical, Inc. | 14 | $296 |
| E.R. Squibb & Sons, L.L.C. | 13 | $286 |
| Lundbeck LLC | 11 | $209 |
| Almatica Pharma LLC | 13 | $182 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $179 |
| Axsome Therapeutics, Inc. | 15 | $170 |
Products named: REXULTI, INGREZZA, VRAYLAR, AUSTEDO XR, FANAPT, COBENFY, LOREEV XR, TRINTELLIX.
Industry payments across WI — which companies pay providers there.
